Niloofar Rahmani

Array ( [id] => 9799635 [patent_doc_number] => 20150011579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-08 [patent_title] => 'FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof' [patent_app_type] => utility [patent_app_number] => 14/369160 [patent_app_country] => US [patent_app_date] => 2012-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13025 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14369160 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9793358 [patent_doc_number] => 20150005302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-01 [patent_title] => '1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME' [patent_app_type] => utility [patent_app_number] => 14/371375 [patent_app_country] => US [patent_app_date] => 2012-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 67341 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14371375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8892289 [patent_doc_number] => 20130165473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-27 [patent_title] => 'Azaquinolinone Derivatives and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 13/717319 [patent_app_country] => US [patent_app_date] => 2012-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50375 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13717319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10001402 [patent_doc_number] => 09045479 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-02 [patent_title] => 'Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors' [patent_app_type] => utility [patent_app_number] => 14/364518 [patent_app_country] => US [patent_app_date] => 2012-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65269 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14364518 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10001400 [patent_doc_number] => 09045478 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-02 [patent_title] => 'Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors' [patent_app_type] => utility [patent_app_number] => 14/364451 [patent_app_country] => US [patent_app_date] => 2012-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34476 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14364451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10940021 [patent_doc_number] => 20140343042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-20 [patent_title] => 'NICOTINE RECEPTOR TARGETED COMPOUNDS AND COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 14/364499 [patent_app_country] => US [patent_app_date] => 2012-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 27057 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14364499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9778196 [patent_doc_number] => 08853403 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-10-07 [patent_title] => 'Heterocyclic compound and light-emitting element, light-emitting device, lighting device, and electronic device using the same' [patent_app_type] => utility [patent_app_number] => 13/707677 [patent_app_country] => US [patent_app_date] => 2012-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 55 [patent_no_of_words] => 22645 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13707677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8866699 [patent_doc_number] => 20130150401 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-13 [patent_title] => 'NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/706602 [patent_app_country] => US [patent_app_date] => 2012-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19694 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13706602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10019531 [patent_doc_number] => 09062002 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-23 [patent_title] => 'Substituted pyridine derivatives as FabI inhibitors' [patent_app_type] => utility [patent_app_number] => 14/361171 [patent_app_country] => US [patent_app_date] => 2012-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46259 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14361171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10906411 [patent_doc_number] => 20140309425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-16 [patent_title] => 'METHOD FOR SYNTHESIZING 1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-3-FORMAMIDINE HYDROCHLORIDE' [patent_app_type] => utility [patent_app_number] => 14/364040 [patent_app_country] => US [patent_app_date] => 2012-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1635 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14364040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9511938 [patent_doc_number] => 20140148430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-29 [patent_title] => 'IMIDAZOPYRIDINES SYK INHIBITORS' [patent_app_type] => utility [patent_app_number] => 13/609068 [patent_app_country] => US [patent_app_date] => 2012-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33675 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13609068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11256785 [patent_doc_number] => 09481677 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-01 [patent_title] => 'Biaryl ether sulfonamides and their use as therapeutic agents' [patent_app_type] => utility [patent_app_number] => 14/355549 [patent_app_country] => US [patent_app_date] => 2012-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56008 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14355549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11256785 [patent_doc_number] => 09481677 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-01 [patent_title] => 'Biaryl ether sulfonamides and their use as therapeutic agents' [patent_app_type] => utility [patent_app_number] => 14/355549 [patent_app_country] => US [patent_app_date] => 2012-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56008 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14355549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11256785 [patent_doc_number] => 09481677 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-01 [patent_title] => 'Biaryl ether sulfonamides and their use as therapeutic agents' [patent_app_type] => utility [patent_app_number] => 14/355549 [patent_app_country] => US [patent_app_date] => 2012-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56008 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14355549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11256785 [patent_doc_number] => 09481677 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-01 [patent_title] => 'Biaryl ether sulfonamides and their use as therapeutic agents' [patent_app_type] => utility [patent_app_number] => 14/355549 [patent_app_country] => US [patent_app_date] => 2012-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56008 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14355549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9902094 [patent_doc_number] => 20150057293 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-26 [patent_title] => 'NEW COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 14/354793 [patent_app_country] => US [patent_app_date] => 2012-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63392 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14354793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9977555 [patent_doc_number] => 09023865 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-05-05 [patent_title] => 'Compounds that are ERK inhibitors' [patent_app_type] => utility [patent_app_number] => 14/353381 [patent_app_country] => US [patent_app_date] => 2012-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63473 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14353381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10919176 [patent_doc_number] => 20140322195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-30 [patent_title] => 'Factor IXA Inhibitors' [patent_app_type] => utility [patent_app_number] => 14/353359 [patent_app_country] => US [patent_app_date] => 2012-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13472 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14353359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10142184 [patent_doc_number] => 09174984 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-03 [patent_title] => 'Chemical compounds' [patent_app_type] => utility [patent_app_number] => 14/353858 [patent_app_country] => US [patent_app_date] => 2012-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50459 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14353858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10628658 [patent_doc_number] => 09346803 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-24 [patent_title] => 'Indomethacin analogs for the treatment of castrate-resistant prostate cancer' [patent_app_type] => utility [patent_app_number] => 14/352421 [patent_app_country] => US [patent_app_date] => 2012-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 18 [patent_no_of_words] => 21162 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14352421 [rel_patent_id] =>[rel_patent_doc_number] =>)